Advertisement

Providers’ perspectives on adherence to hormonal therapy in breast cancer survivors. Is there a role for the digital health feedback system?

  • Alejandra Hurtado-de-Mendoza
  • Mark L. Cabling
  • Asma Dilawari
  • Jeanine Warisse Turner
  • Nicole C. Fernández
  • Alesha Henderson
  • Qi Zhu
  • Sara Gómez-Trillos
  • Vanessa B. Sheppard
Original Paper

Abstract

Despite the benefits of hormonal therapy (HT) adherence remains suboptimal in ER positive breast cancer patients. Medication adherence is challenging to assess and tends to be overestimated. The Digital Health Feedback System (DHFS) consists of an ingestible sensor attached to a pill that sends intake date and time to a smart phone or computer. Patients can share this information with health care providers and other persons. The DHFS can also send reminders. This mixed methods study examined providers’ perceptions of HT medication adherence. The potential role of the DHFS in enhancing medication tracking and adherence was also explored. We conducted semi-structured interviews with key informants (N = 10). Questions examined perceptions about adherence barriers and facilitators, challenges tracking adherence, and views on the DHFS. Findings informed the development of a survey that was administered online (N = 19). Providers emphasized the importance of fostering open and trustful communication around adherence. The most mentioned challenges to assessing adherence were the patient not disclosing discontinuation immediately (78.9%) and over-reporting adherence (57.9%). The perceived potential benefits of DHFS were the ability to track adherence better (94.7%) and reminders to take the medication (68.4%). Safety to ingest a sensor was a major perceived barrier (8 4.2%). Interventions that target providers and doctor-patient communication are warranted to enhance adherence and reduce communication delays around HT discontinuation. DHFS has the potential to enhance HT adherence by directly targeting barriers. Future studies should also examine the feasibility of adopting the DHFS with cancer patients.

Keywords

Patient-doctor communication Hormonal therapy adherence Digital health feedback system 

Notes

Acknowledgements

The project described was supported by the National Cancer Institute (Sheppard: PI, grant number: R01CA154848). This project was also supported by the Georgetown-Howard Universities Center for Clinical and Translational Science (GHUCCTS) by Federal Funds, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), through the Clinical and Translational Science Awards Program (CTSA) (Award Numbers: KL2TR001432; PI Hurtado de Mendoza) and Georgetown University Internal Grant (‘Reflective Engagement for the Public Interest’, MPIs Sheppard and Hurtado-de-Mendoza). The content is solely responsibility of the authors and does not necessarily represent the official views of the National Center for Advancing Translational Science, the National Institute of Health.

Compliance with ethical standards

The study was approved by Georgetown University Institutional Review Board.

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All procedures in this study have been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable standards.

References

  1. 1.
    Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Adjuvant tamoxifen: longer against shorter (ATLAS) collaborative group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805–16.CrossRefGoogle Scholar
  2. 2.
    Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer ResTreat. 2011;126:529–37.CrossRefGoogle Scholar
  3. 3.
    Early Breast Cancer Trialists’ Collaborative Group, (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.CrossRefGoogle Scholar
  4. 4.
    Huiart L, Ferdynus C, Giorgi R. A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians. Breast Cancer ResTreat. 2013;138:325–8.CrossRefGoogle Scholar
  5. 5.
    Nekhlyudov L, Li L, Ross-Degnan D, Wagner A. Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat. 2011;130:681–9.CrossRefGoogle Scholar
  6. 6.
    Moon Z, Moss-Morris R, Hunter MS, Carlisle S, Hughes LD. Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review. Patient Preference and Adherence. 2017;11:305–22.CrossRefGoogle Scholar
  7. 7.
    Ong LML, de Haes JCJM, Hoos AM, Lammes FB. Doctor-patient communication: a review of the literature. Soc Sci Med. 1995;40:903–18.CrossRefGoogle Scholar
  8. 8.
    Haskard Zolnierek KB, DiMatteo MR. Physician communication and patient adherence to treatment: a meta-analysis. Med Care. 2009;47:826–34.CrossRefGoogle Scholar
  9. 9.
    Wassermann J, Rosenberg SM. Treatment decisions and adherence to adjuvant endocrine therapy in breast Cancer. Current Breast Cancer Reports. 2017;9:100–10.CrossRefGoogle Scholar
  10. 10.
    Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21:1074–90.CrossRefGoogle Scholar
  11. 11.
    Rivero-Mendez M, Dawson-Rose CS, Solis-Baez SS. A qualitative study of providers' perception of adherence of women living with HIV/AIDS in Puerto Rico. Qual Rep. 2010;15:232.Google Scholar
  12. 12.
    Tarn DM, Mattimore TJ, Bell DS, Kravitz RL, Wenger NS. Provider views about responsibility for medication adherence and content of physician-older patient discussions. J Am Geriatr Soc. 2012;60:1019–26.CrossRefGoogle Scholar
  13. 13.
    Eisenberger U, Wuthrich RP, Bock A, Ambuhl P, Steiger J, Intondi A, et al. Medication adherence assessment: high accuracy of the new ingestible sensor system in kidney transplants. Transplantation. 2013;96:245–50.CrossRefGoogle Scholar
  14. 14.
    Belknap R, Weis S, Brookens A, Au-Yeung KY, Moon G, DiCarlo L, et al. Feasibility of an ingestible sensor-based system for monitoring adherence to tuberculosis therapy. PLoS One. 2013;8:e53373.CrossRefGoogle Scholar
  15. 15.
    Kane JM, Perlis RH, DiCarlo LA, Au-Yeung K, Duong J, Petrides G. First experience with a wireless system incorporating physiologic assessments and direct confirmation of digital tablet ingestions in ambulatory patients with schizophrenia or bipolar disorder. JClinPsychiatry. 2013;74:533.Google Scholar
  16. 16.
    Hurtado-de-Mendoza* A, Cabling* M, Sheppard VB. Rethinking agency and medical adherence technology: applying actor network theory to the case study of digital pills. Nurs Inq. 2015;22:326–35.CrossRefGoogle Scholar
  17. 17.
    Hill CE, Knox S, Thompson BJ, Williams EN, Hess SA, Research LNCQ. Consensual qualitative research: An update. J Couns Psychol. 2005;52:196–205.CrossRefGoogle Scholar
  18. 18.
    SocioCultural Research Consultants L. Dedoose Version 7.0.23, web application for managing, analyzing, and presenting qualitative and mixed method research data  2016.Google Scholar
  19. 19.
    Ayres LR, Baldoni ADO, De Sa Borges AP, Pereira LRL. Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer. IntJClinPharm. 2014;36:45–54.Google Scholar
  20. 20.
    Cella D, Fallowfield LJ. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer ResTreat. 2008;107:167–80.CrossRefGoogle Scholar
  21. 21.
    Lash T, Fox M, Westrup J, Fink A, Silliman R. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat. 2006;99:215–20.CrossRefGoogle Scholar
  22. 22.
    Atkins L, Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer. 2006;42:2271–6.CrossRefGoogle Scholar
  23. 23.
    Grunfeld EA, Hunter MS, Sikka P, Mittal S. Adherence beliefs among breast cancer patients taking tamoxifen. Patient EducCouns. 2005;59:97–102.CrossRefGoogle Scholar
  24. 24.
    Simon R, Latreille J, Matte C, Desjardins P, Bergeron E. Adherence to adjuvant endocrine therapy in estrogen receptor–positive breast cancer patients with regular follow-up. Can J Surg. 2014;57:26–32.CrossRefGoogle Scholar
  25. 25.
    Leonard R, Lee L, Harrison ME. Impact of side-effects associated with endocrine treatment for advanced breast cancer: clinicians' and patients' perceptions. Breast. 1996;5:259e269.CrossRefGoogle Scholar
  26. 26.
    Jacob Arriola KR, Mason TA, Bannon KA, Holmes C, Powell CL, Horne K, et al. Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients. Patient Educ Couns. 2014;95:98–103.CrossRefGoogle Scholar
  27. 27.
    Liu Y, Malin JL, Diamant AL, Thind A, Maly RC. Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast Cancer ResTreat. 2013;137:829–36.CrossRefGoogle Scholar
  28. 28.
    Neugut AI, Hillyer GC, Kushi LH, Lamerato L, Leoce N, Nathanson SD, et al. Noninitiation of adjuvant chemotherapy in women with localized breast cancer: the breast cancer quality of care study (BQUAL). Breast Cancer Res Treat. 2012;134:419–28.CrossRefGoogle Scholar
  29. 29.
    Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM. Patient centered experiences in breast Cancer: predicting long-term adherence to tamoxifen use. Med Care. 2007;45:431–9.CrossRefGoogle Scholar
  30. 30.
    Cluze C, Rey D, Huiart L, BenDiane MK, Bouhnik AD, Berenger C, et al. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. AnnOncol. 2012;23:882–90.Google Scholar
  31. 31.
    Davidson B, Vogel V, Wickerham L. Oncologist-patient discussion of adjuvant hormonal therapy in breast cancer: results of a linguistic study focusing on adherence and persistence to therapy. The Journal of Supportive Oncology. 2007;5:139.Google Scholar
  32. 32.
    Kirk MC, Hudis CA. Insight into barriers against optimal adherence to Oral hormonal therapy in women with breast Cancer. Clinical Breast Cancer. 2008;8:155–61.CrossRefGoogle Scholar
  33. 33.
    Leighl N, Gattellari M, Butow P, Brown R, Tattersall MHN. Discussing adjuvant Cancer therapy. J Clin Oncol. 2001;19:1768–78.CrossRefGoogle Scholar
  34. 34.
    Hurtado-de-Mendoza A, Cabling ML, Lobo T, Dash C, Sheppard VB. Behavioral interventions to enhance adherence to hormone therapy in breast Cancer survivors: a systematic literature review. Clinical Breast Cancer. 2016;16:247–55.CrossRefGoogle Scholar
  35. 35.
    McCowan C, Wang S, Thompson AM, Makubate B, Petrie DJ. The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study. Br J Cancer. 2013;109:1172–80.CrossRefGoogle Scholar
  36. 36.
    Winn AN, Dusetzina SB. The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer. Pharmacoepidemiol Drug Saf. 2016;25:953–9.CrossRefGoogle Scholar
  37. 37.
    Mougalian SS, Epstein LN, Jhaveri AP, Han G, Abu-Khalaf M, Hofstatter EW, et al. Bidirectional text messaging to monitor endocrine therapy adherence and patient-reported outcomes in breast Cancer. JCO Clinical Cancer Informatics. 2017;(1):1–10.Google Scholar
  38. 38.
    Varnell CD, Rich KL, Nichols M, Dahale D, Goebel JW, Pai ALH, et al. Assessing barriers to adherence in routine clinical care for pediatric kidney transplant patients. Pediatr Transplant. 2017;21:e13027.CrossRefGoogle Scholar
  39. 39.
    Mehta P, Steinberg EA, Kelly SL, Buchanan C, Rawlinson AR. Medication adherence among adolescent solid-organ transplant recipients: a survey of healthcare providers. Pediatr Transplant. 2017;21.CrossRefGoogle Scholar
  40. 40.
    Ramsey RR, Zhang N, Modi AC. The stability and influence of barriers to medication adherence on seizure outcomes and adherence in children with epilepsy over 2 years. J Pediatr Psychol. 2017.Google Scholar
  41. 41.
    Jordan TA, Hennenfent JA, Lewin JJ, Nesbit TW, Weber R. DP. Elevating pharmacists' scope of practice through a health-system clinical privileging process. Am J Health Syst Pharm. 2016;73:1395–405.CrossRefGoogle Scholar
  42. 42.
    Takaki H, Abe T, Hagihara A. Physicians' and pharmacists' information provision and patients' psychological distress. J Interprof Care. 2017;31:575–82.CrossRefGoogle Scholar
  43. 43.
    The Canadian Interprofessional Health Collaborative, (CIHC). A National Interprofessional Competency Framework 2010.Google Scholar

Copyright information

© IUPESM and Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Alejandra Hurtado-de-Mendoza
    • 1
  • Mark L. Cabling
    • 2
  • Asma Dilawari
    • 3
  • Jeanine Warisse Turner
    • 4
  • Nicole C. Fernández
    • 4
  • Alesha Henderson
    • 5
  • Qi Zhu
    • 1
  • Sara Gómez-Trillos
    • 1
  • Vanessa B. Sheppard
    • 5
  1. 1.Georgetown University Medical CenterWashingtonUSA
  2. 2.King’s College LondonLondonUK
  3. 3.MedStar Georgetown UniversityWashingtonUSA
  4. 4.Communication, Culture & Technology ProgramGeorgetown UniversityWashingtonUSA
  5. 5.Virginia Commonwealth UniversityRichmondUSA

Personalised recommendations